Disease-Targeted Therapies and eGFR Slope over 2 Years in IgA Nephropathy: A Systematic Review and Network Meta-Analysis

Background: Several disease-targeted therapies for IgA nephropathy have reported effects on eGFR slope over 2 years or longer in phase 3 trials, but they have not been compared directly. We compared their effects on the annualized total eGFR slope. Methods: We searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from January 2018 and reviewed nephrology congress abstracts. Randomized trials reporting the annualized eGFR slope over at least 96 weeks were eligible. Placebo-controlled trials were combined in a frequentist network meta-analysis. The p

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.